Table 2 Patients receiving cancer care in certified cancer networks by stage and treatment sequences (n = 157,871) in Upper Franconia, Germany between 2017 and 2023
|  | Cancer care in certified structures (n = 79,466; 50.3%) | Cancer care in non-certified structures (n = 78,405; 49.7%) | Overall | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Absolute | In % | 95% CI | Absolute | In % | 95% CI | |||||
Stage 0 | |||||||||||
 Diagnosis | 881 | 73.8% | 70.9% | 76.6% | 312 | 26.2% | 23.4% | 29.1% | 1,193 | ||
 Surgery | 1,399 | 77.7% | 75.4% | 79.8% | 401 | 22.3% | 20.2% | 24.6% | 1,800 | ||
 Chemotherapy | 729 | 77.9% | 74.7% | 80.8% | 207 | 22.1% | 19.2% | 25.3% | 936 | ||
 Radiotherapy | 510 | 77.7% | 73.9% | 81.2% | 146 | 22.3% | 18.8% | 26.1% | 656 | ||
 Overall | 3,519 | 76.8% | 75.3% | 78.1% | 1,066 | 23.2% | 21.9% | 24.7% | 4,585 | ||
Stage I | |||||||||||
 Diagnosis | 5,203 | 49.7% | 48.6% | 50.8% | 5,263 | 50.3% | 49.2% | 51.4% | 10,466 | ||
 Surgery | 7,945 | 60.1% | 59.2% | 61.1% | 5,267 | 39.9% | 38.9% | 40.8% | 13,212 | ||
 Chemotherapy | 2,944 | 70.3% | 68.7% | 71.8% | 1,245 | 29.7% | 28.2% | 31.3% | 4,189 | ||
 Radiotherapy | 2,020 | 70.0% | 68.0% | 71.9% | 866 | 30.0% | 28.1% | 32.0% | 2,886 | ||
 Overall | 18,112 | 58.9% | 58.3% | 59.5% | 12,641 | 41.1% | 40.5% | 41.7% | 30,753 | ||
Stage II | |||||||||||
 Diagnosis | 3,304 | 54.7% | 53.3% | 56.1% | 2,735 | 45.3% | 43.9% | 46.7% | 6,039 | ||
 Surgery | 5,150 | 65.2% | 64.0% | 66.4% | 2,750 | 34.8% | 33.6% | 36.0% | 7,900 | ||
 Chemotherapy | 3,264 | 65.8% | 64.3% | 67.3% | 1,697 | 34.2% | 32.7% | 35.7% | 4,961 | ||
 Radiotherapy | 1,941 | 69.5% | 67.5% | 71.4% | 853 | 30.5% | 28.6% | 32.5% | 2,794 | ||
 Overall | 13,659 | 63.0% | 62.2% | 63.7% | 8,035 | 37.0% | 36.3% | 37.8% | 21,694 | ||
Stage III | |||||||||||
 Diagnosis | 2,090 | 49.0% | 47.3% | 50.8% | 2,172 | 51.0% | 49.2% | 52.7% | 4,262 | ||
 Surgery | 3,758 | 61.6% | 60.2% | 63.0% | 2,345 | 38.4% | 37.0% | 39.8% | 6,103 | ||
 Chemotherapy | 3,266 | 62.0% | 60.5% | 63.5% | 2,001 | 38.0% | 36.5% | 39.5% | 5,267 | ||
 Radiotherapy | 1,505 | 60.5% | 58.3% | 62.7% | 981 | 39.5% | 37.3% | 41.7% | 2,486 | ||
 Overall | 10,619 | 58.6% | 57.8% | 59.4% | 7,499 | 41.4% | 40.6% | 42.2% | 18,118 | ||
Stage IV | |||||||||||
 Diagnosis | 1,160 | 52.8% | 50.4% | 55.1% | 1,039 | 47.2% | 44.9% | 49.6% | 2,199 | ||
 Surgery | 2,198 | 65.7% | 63.8% | 67.5% | 1,148 | 34.3% | 32.5% | 36.2% | 3,346 | ||
 Chemotherapy | 2,503 | 63.5% | 61.8% | 65.2% | 1,438 | 36.5% | 34.8% | 38.2% | 3,940 | ||
 Radiotherapy | 826 | 55.1% | 52.2% | 57.9% | 674 | 44.9% | 42.1% | 47.8% | 1,500 | ||
 Overall | 6,687 | 60.9% | 59.8% | 61.9% | 4,299 | 39.1% | 38.1% | 40.2% | 10,985 | ||
Missing stage | |||||||||||
 Diagnosis | 8,494 | 30.6% | 30.0% | 31.2% | 19,291 | 69.4% | 68.8% | 70.0% | 27,785 | ||
 Surgery | 4,631 | 45.7% | 44.6% | 46.8% | 5,507 | 54.3% | 53.2% | 55.4% | 10,138 | ||
 Chemotherapy | 10,966 | 43.5% | 42.8% | 44.2% | 14,227 | 56.5% | 55.8% | 57.2% | 25,193 | ||
 Radiotherapy | 2,782 | 32.3% | 31.2% | 33.5% | 5,818 | 67.7% | 66.5% | 68.8% | 8,600 | ||
 Overall | 26,873 | 37.5% | 37.1% | 37.9% | 44,843 | 62.5% | 62.1% | 62.9% | 71,716 | ||